Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Rule

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Advances in Radiation Oncology|December 11, 2025
Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin's lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial ProtocolOmran Saifi, Scott C Lester, William G Rule, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|September 19, 2018
Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non-Small Cell Lung Cancer: The Mayo Clinic ExperienceCorey J Hobbs, Stephen J Ko, Nitesh N Paryani, et al.
Practical Radiation Oncology|July 17, 2019
A Comparison of Patient-Reported Health-Related Quality of Life During Proton Versus Photon Chemoradiation Therapy for Esophageal CancerAurelie Garant, Thomas J Whitaker, Grant M Spears, et al.
Advances in Radiation Oncology|October 14, 2021
Multi-institutional Comparison of Intensity Modulated Photon Versus Proton Radiation Therapy in the Management of Squamous Cell Carcinoma of the AnusJahan J Mohiuddin, Krishan R Jethwa, Nikhil Grandhi, et al.
International Journal of Radiation Oncology, Biology, Physics|December 23, 2022
Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin LymphomaOmran Saifi, William G Breen, Scott C Lester, et al.
Haematologica|June 15, 2023
Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphomaOmran Saifi, William G Breen, Scott C Lester, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 31, 2026
Optimizing low dose radiotherapy for indolent lymphomas: comparing 8 Gy in 2 fractions to 4 Gy in 2 fractionsJessica F Burlile, William S Harmsen, Sydney D Suddendorf, et al.
Blood Advances|July 19, 2024
Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapyOmran Saifi, William G Breen, Scott C Lester, et al.
Blood Advances|January 11, 2024
Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapyJessica F Burlile, Kelsey M Frechette, William G Breen, et al.
Journal of Gastrointestinal Oncology|November 18, 2021
Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapyHunter C Gits, Amy H Tang, William S Harmsen, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Advances in Radiation Oncology|December 11, 2025
Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin's lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial ProtocolOmran Saifi, Scott C Lester, William G Rule, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|September 19, 2018
Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non-Small Cell Lung Cancer: The Mayo Clinic ExperienceCorey J Hobbs, Stephen J Ko, Nitesh N Paryani, et al.
Practical Radiation Oncology|July 17, 2019
A Comparison of Patient-Reported Health-Related Quality of Life During Proton Versus Photon Chemoradiation Therapy for Esophageal CancerAurelie Garant, Thomas J Whitaker, Grant M Spears, et al.
Advances in Radiation Oncology|October 14, 2021
Multi-institutional Comparison of Intensity Modulated Photon Versus Proton Radiation Therapy in the Management of Squamous Cell Carcinoma of the AnusJahan J Mohiuddin, Krishan R Jethwa, Nikhil Grandhi, et al.
International Journal of Radiation Oncology, Biology, Physics|December 23, 2022
Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin LymphomaOmran Saifi, William G Breen, Scott C Lester, et al.
Haematologica|June 15, 2023
Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphomaOmran Saifi, William G Breen, Scott C Lester, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 31, 2026
Optimizing low dose radiotherapy for indolent lymphomas: comparing 8 Gy in 2 fractions to 4 Gy in 2 fractionsJessica F Burlile, William S Harmsen, Sydney D Suddendorf, et al.
Blood Advances|July 19, 2024
Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapyOmran Saifi, William G Breen, Scott C Lester, et al.
Blood Advances|January 11, 2024
Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapyJessica F Burlile, Kelsey M Frechette, William G Breen, et al.
Journal of Gastrointestinal Oncology|November 18, 2021
Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapyHunter C Gits, Amy H Tang, William S Harmsen, et al.
Pageof 9